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Outer membrane and membrane vesicles (OMV/MV) are released from bacteria and
participate in cell communication, biofilm formation and host-pathogen interactions.
Peptidylarginine deiminases (PADs) are phylogenetically conserved enzymes that
catalyze post-translational deimination/citrullination of proteins, causing structural
and functional changes in target proteins. PADs also play major roles in the
regulation of eukaryotic extracellular vesicle release. Here we show phylogenetically
conserved pathways of PAD-mediated OMV/MV release in bacteria and describe
deiminated/citrullinated proteins in E. coli and their derived OMV/MVs. Furthermore,
we show that PAD inhibitors can be used to effectively reduce OMV/MV release, both
in Gram-negative and Gram-positive bacteria. Importantly, this resulted in enhanced
antibiotic sensitivity of both E. coli and S. aureus to a range of antibiotics tested.
Our findings reveal novel strategies for applying pharmacological OMV/MV-inhibition
to reduce antibiotic resistance.
Keywords: outer-membrane vesicles (OMVs), peptidylarginine deiminase (PAD), deimination/citrullination,
antibiotic sensitivity, E. coli VCS257, S. aureus subsp. aureus Rosenbach
INTRODUCTION
Outer membrane vesicles (OMVs), and membrane vesicles (MVs), are released from
Gram-negative and Gram-positive bacteria and participate in bacterial communication, facilitating
the transfer of cargo molecules (Dorward and Garon, 1990; Li et al., 1998; Fulsundar et al., 2014;
Jan, 2017; Toyofuku et al., 2019). OMVs are released in greater abundance from Gram-negative
than Gram-positive bacteria, are crucial for bacterial survival and form part of the stress response
(McBroom and Kuehn, 2007;Macdonald and Kuehn, 2013; Jan, 2017). Research on bacterial OMVs
has grown rapidly in recent years, including their use as bioengineered drug delivery vehicles
(Gujrati et al., 2014; Bitto and Kaparakis-Liaskos, 2017) and in vaccine development (Gaillard et al.,
2014; Choi et al., 2015; Alves et al., 2016; Raeven et al., 2016; Wang et al., 2017).
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Peptidylarginine deiminases (PADs) are a group of calcium-
activated enzymes that are preserved throughout phylogeny
from bacteria to mammals and catalyze the post-translational
deimination/citrullination of arginine residues to citrulline,
causing structural, and functional changes in target proteins
(Vossenaar et al., 2003; Wang and Wang, 2013; Witalison
et al., 2015; Magnadóttir et al., 2018). Five mammalian PAD
isozymes have been identified which participate in physiological
and pathophysiological processes, including autoimmune and
neurodegenerative diseases, cancer and sepsis (Wang and Wang,
2013; Witalison et al., 2015; Kosgodage et al., 2017, 2018; Lange
et al., 2017; Biron et al., 2018; Costa et al., 2018). Recent
studies have highlighted novel PAD-mediated mechanisms of
extracellular vesicle (EV) release in eukaryotic cells (Kholia et al.,
2015; Kosgodage et al., 2017, 2018; Gavinho et al., 2019) but
a link to conserved mechanisms in bacterial OMV/MV release
has hitherto not been made. While several PAD isozymes, with
different preferences for target proteins, are present higher in
phylogeny, in bacteria only one PAD form has been described.
For example in Porphyromonas gingivalis, a Gram-negative
bacterium, the association of PAD and its citrullinome has been
linked to neo-epitope generation in oral cavity disease and
rheumatoid arthritis (Maresz et al., 2013; Gully et al., 2014;
Stobernack et al., 2016; Bereta et al., 2019). However, although
an arginine deiminase (AD) has been identified in the Eschericia
coli genome (GenBank: EDV68547.1), also a Gram-negative
bacterium, no significant data is available to confirm the presence
of an associated citrullinome. Furthermore, an AD has also been
identified in Staphylococcus aureus (GenBank: BBA25170.1), a
Gram-positive bacterium.
Our previous studies established that EV release from
cancer cells is largely PAD-driven, can be effectively inhibited
using pharmacological PAD inhibitors and that such inhibition
sensitizes cancer cells to chemotherapy (Kholia et al., 2015;
Kosgodage et al., 2017, 2018). Therefore, we set out to investigate
if this could be a phylogenetically conserved mechanism and in
the same vein, be exploited to sensitize bacteria to antibiotics.
The role of OMVs in biofilm formation and in protecting
biofilms via adsorption of antimicrobial agents has indeed been
previously recognized (Schooling and Beveridge, 2006; Manning
and Kuehn, 2011; Toyofuku et al., 2019). Thus, application of
OMV inhibition could potentially lower resistance to antibiotics
and be useful in minimizing multi-drug resistance associated
with antibiotic treatment.
Using a range of antibiotics, we determined the effect of
several PAD-specific inhibitors on changes in OMV/MV release
and on antibiotic sensitivity of Gram-negative (E. coli VCS257)
and Gram-positive bacteria (S. aureus subsp. aureus Rosenbach).
The PAD inhibitors tested were first generation pan-PAD
inhibitor Cl-amidine (Luo et al., 2006), second generation
pan-PAD inhibitor BB-Cl-amidine (Knight et al., 2014), PAD2
inhibitor AMF30a (Muth et al., 2017), and PAD4 inhibitor
GSK199 (Lewis et al., 2015). The following range of antibiotics
was tested in combination with the OMV/MV inhibitors:
(i) Colistin (Polymyxin E), which acts on the lipoglycans
and endotoxins of the Gram-negative bacterial cell membrane
(Falagas et al., 2005; Livermore et al., 2011; Yahav et al., 2012;
Yu et al., 2019); (ii) Vancomycin, which alters the permeability
of the cell membrane and selectively inhibits ribonucleic acid
synthesis (Watanakunakorn, 1984). It is effective against Gram-
positive bacteria, including Staphylococcus, Streptococcus, and
Listeria and prescribed for serious skin, blood-borne and
joint infections as well as meningitis caused by methicillin-
resistant Staphylococcus aureus (MRSA) (Ng et al., 2014); (iii)
Rifampicin, which inhibits DNA-dependent RNA polymerase
activity, suppressing the initiation of RNA synthesis (Campbell
et al., 2001). It is effective against a broad spectrum of
bacteria, mainly Gram-positive cocci (van Ingen et al., 2011);
(iv) Kanamycin, which binds to the bacterial 30S ribosomal
subunit, causing misreading of t-RNA and inhibition of bacterial
protein synthesis (Hoerr et al., 2016). It is active against
most Gram-negative bacteria and some Gram-positive bacteria
(Salian et al., 2012); (v) Erythromycin, which inhibits bacterial
protein synthesis by binding to bacterial 50S ribosomal subunits
(Ianaro et al., 2000). It is effective against Gram-positive
bacteria including Staphylococci, Streptococci and Pneumococci
and Gram-negative sporing and non-sporing gut anaerobes, such
as E. coli (Jelic´ and Antolovic´, 2016).
Here we show that OMV/MV release can be regulated via
PAD-mediated pathways both in E. coli VCS257 and S. aureus
subsp. aureus Rosenbach and that this can be exploited to
enhance antibiotic effectivity of selected antibiotics in both
Gram-negative and Gram-positive bacteria. Furthermore, in E.
coli we identified deiminated/citrullinated proteins both in the
bacterial cells and in derived OMVs, indicative of bacterial
communication via lateral transfer of deiminated proteins.
MATERIALS AND METHODS
Preparation of Outer Membrane Vesicles
(OMVs) and Membrane Vesicles (MVs)
E. coli (VCS257, Agilent, La Jolla, CA) and S. aureus subsp.
aureus Rosenbach (ATCC 29247; CDC73-57501) cultures were
grown for 24 h at 37◦C (static culture). The growth phase before
vesicle isolation was exponential, as assessed by optical density
(OD600) before overnight incubation and for 4 h the following
day, to ensure that bacteria were in log phase; the volume of
the cultures was 20ml. For OMV/MV-associated experiments,
the bacterial growth medium (Luria-Bertani (LB) broth) and
Dulbecco’s phosphate buffered saline (DPBS)S were pre-treated
before use by ultracentrifugation at 100,000 g (SW60Ti rotor,
Beckmann L60 ultracentrifuge) for 24 h, to ensure that the
medium used was minimally contaminated with extracellular
vesicles (EVs).
The OMV/MVs were isolated from the supernatant of the
bacterial culture medium as follows: The supernatant was
initially centrifuged once at 400 g (F-34-6-38 rotor, Eppendorf
5804, U.S.A.) for 10min to remove the cells. Thereafter,
the supernatant was centrifuged at 4,000 g (F-34-6-38 rotor,
Eppendorf 5804) for 1 h at 4◦C to remove cell debris. The
resultant supernatant was then centrifuged at 100,000 g (SW60Ti
rotor, Beckmann L60 ultracentrifuge, Beckman Coulter, U.S.A.)
for 1 h at 4◦C for isolation of OMVs. The isolated OMV/MV
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pellet was then resuspended in Dulbecco’s phosphate-buffered
saline (DPBS; ultracentrifuged and sterile filtered using a 0.22µm
filter) and filtered through an 0.45µm filter before the second
ultracentrifigation step at 100,000 g for 1 h at 4◦C. The
resulting OMV/MV pellet was thereafter resuspended in 100
µl sterile filtered (0.22µm) DPBS and the isolated OMV/MV
pellets were either used immediately, or stored at −80◦C for
further experiments.
Nanoparticle Tracking Analysis (NTA)
of OMV/MV
For NTA analysis, isolated OMV and MV pellets, respectively,
prepared as described above, were resupended in 100 µl sterile
filtered DPBS and then diluted 1/200 before quantification
to assess vesicle size, based on Brownian motion, using the
Nanosight LM10, with a 405 nm diode laser (Malvern, U.K.).
Numbers of particles per frame were kept at approximately
30, and five individual 60 s videos were recorded using a
sCMOS camera for each sample to create the respective size
distribution histograms. OMVs/MVs were further characterized
by transmission electron microscopy (TEM) and Western
blotting as described below.
Transmission Electron Microscopy Imaging
A suspension of isolated OMVs/MVs (1.4× 108 vesicles/ml) was
used for TEM imaging. Mesh copper grids were prepared with
glow discharged carbon support films and 10 µl of OMV/MV
samples applied to the grid and incubated for 2min. The grids
were then washed five times with 50 µl of 1% aqueous uranyl
acetate. The last drop was left to incubate on the grid for 1.5min
before being wicked off by torn filter paper. Grids were left to dry
for 5min before being viewed. Micrographs were taken with a
JEOL JEM 1230 transmission electron microscope (JEOL, Japan)
operated at 80 kV at a range of magnification mainly around a
magnification of 80,000–100,000. Digital images were recorded
on a Morada CCD camera (EMSIS, Germany) and processed via
iTEM (EMSIS, Germany).
Western Blotting for Membrane
Vesicle Characterization
Protein was isolated from the OMV/MV pellets using Bacterial
Protein Extraction Reagent (B-PER, ThermoFisher Scientific,
U.K.), pipetting gently and shaking the pellets on ice for
2 h, where after samples were centrifuged at 16,000 g at
4◦C for 20min and the resulting supernatant collected for
protein analysis. Samples were electrophoresed under reducing
conditions by SDS-PAGE on 4–20% TGX gels (BioRad,
U.K.), followed by semi-dry Western blotting. Membranes
were blocked in 5% BSA in TBS-T at RT for 1 h. The
membranes were incubated overnight at 4◦C with the anti-
OmpC (Outer-membrane protein C antibody; orb6940, Biorbyt,
U.K.; diluted 1/1,000 in TBS-T). The membranes were washed
3 × 10min in TBS-T, incubated for 1 h in anti-rabbit-HRP
conjugated secondary antibody (BioRad, U.K.) at RT, followed
by visualization using ECL (Amersham, U.K.) and the UVP
BioDoc-ITTM System (U.K.).
Immunoprecipitation (IP) and LC-MS/MS
Analysis of Deiminated and PAD4 Bound
Proteins From E. coli VCS257 Cells and
Derived OMVs
To determine the presence of deiminated/citrullinated proteins
and PAD4 bound proteins from E. coli VCS257 and derived
OMVs, protein extracts were prepared using Bacterial Protein
Extraction Reagent (B-PER, ThermoFisher Scientific, U.K.),
according to the manufacturer’s instructions. In brief, bacterial
cells and OMVs were centrifuged at 5,000 g for 10min to
obtain a pellet. Two microliter of lysozyme and 2 µL of
DNase I per 1mL of B-PER Reagent was added along with
EDTA-free protease inhibitors (ThermoFisher Scientific). Four
mL of B-PER Reagent per gram of cell pellet was added.
The suspension was pipetted up and down until it was
homogeneous. The suspension was incubated for 10–15min at
room temperature. The lysate was centrifuged at 16,000 g for
5min to separate soluble proteins from the insoluble proteins.
Proteins were thereafter immunoprecipitated, using the Catch
and Release R© v2.0 Reversible Immunoprecipitation System
(Merck, U.K.), according to the manufacturer’s instructions,
in conjunction with the pan-deimination F95 (MABN328,
Merck) antibody (both for E. coli and derived OMVs) or
the PAD4 (ab96758, Abcam) antibody (for E. coli cells only).
The F95 pan-deimination specific antibody has been developed
against a deca-citrullinated peptide and specifically detects
proteins modified by citrullination (Nicholas and Whitaker,
2002). F95 or PAD4 bound proteins, respectively, were eluted
from the columns according to the manufacturer’s instructions
(MERCK), using the supplied elution buffer (non-reducing
or a reducing elution buffer, which was supplemented with
5% beta-mercapthoethanol) and thereafter further analyzed by
Western blotting, under reducing conditions, and by liquid
chromatography-mass spectrometry (LC-MS/MS).
Western Blotting Analysis of
Citrullinated/Deiminated Proteins From
E. coli VCS257 Cells and Derived OMVs
In order to compare protein profiles of deiminated proteins
between E. coli and E. coli OMVs, total protein lysates and IP
protein eluates were subjected to Western blot analysis. Briefly,
samples were boiled for 5min at 100◦C in 2x Laemmli sample
buffer (BioRad, U.K.). Protein (20 µg per sample) was separated
by SDS-PAGE using 4–20% Mini-Protean TGX protein gels
(BioRad, U.K) and transferred to nitrocellulose membranes.
Even loading was assessed using Ponceau S staining (Sigma,
U.K.) and membranes were then blocked in 5% bovine serum
albumin (BSA) in Tris buffered saline with 0.1% Tween20 (TBS-
T) for 1 h, followed by incubation at 4 ◦C overnight with
the primary antibodies: pan-deimination antibody F95 (1:2,000;
MABN328), PAD2 (1:1,000; ab50257), PAD3 (1:1,000; ab169479)
and PAD4 (1:1,000; ab96758), respectively. Membranes were
washed three times in TBS-T, incubated at room temperature for
1 h with HRP-conjugated secondary antibodies: anti-mouse IgM
and anti-rabbit IgG, respectively (both 1:4,000; BioRad, U.K.),
followed by six 10min washes in TBS-T, before visualization
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using ECL (Amersham, U.K.) and the UVP BioDoc-ITTM
System (U.K.).
Liquid Chromatography-Mass
Spectrometry (LC-MS/MS) Analysis
For identification of deiminated/citrullinated proteins and
PAD4 bound proteins, respectively, in E. coli cell lysate
and OMV lysates, the F95 and PAD4 bound eluates were
subjected to LC-MS/MS analysis, which was carried out
at the Proteomics Service at the Barts Cancer Institute
(Queen Mary University, U.K.). For identification of protein
hits the peak list files were submitted to in-house Mascot
(Matrix Science).
Effects of PAD Inhibitors on Bacterial
OMV/MV Release and Cell Viability
E. coli and S. aureus were cultivated using EV-free Müeller-
Hinton broth for 24 h. Culture condition were as follows: An
inoculate of 0.1ml of bacteria were grown at exponential phase
overnight, as assessed by OD600; the volume of the cultures
was 20ml. The cells were washed using DPBS at 4,000 g for
10min and seeded in triplicate in micro centrifuge tubes. The
PAD inhibitors were added in triplicates and incubated for 1 h
at 37◦C as follows: PAD2 inhibitor AMF30a (5µM), PAD4
inhibitor, GSK199 (10µM), pan-PAD inhibitor Cl-amidine
(50µM), and BB-Cl-amidine (5µM). Cell viability of bacteria
in the presence of the different PAD inhibitors was assessed
by counting the number (no) of surviving bacterial colonies
on the plates. The no. of colonies (viable cells), inoculating
volume and dilution factor of the bacterial culture used was
used to calculate the viable cells in colony forming unit
(cfu/ml) (cfu/ml = (no. of colonies x dilution factor)/volume
of culture plate). OMV/MV isolation following treatment was
carried out as described above and changes in OMV/MV release
were assessed by quantifying numbers of OMVs/MVs by NTA
analysis using the Nanosight LM10 as described above. The
experiment was repeated three times and replicate histograms
were averaged.
Disc Diffusion Test
E. coli VCS257 and S. aureus subsp. aureus Rosenbach nutrient
agar plates were prepared and sterile paper disks were soaked in
the PAD inhibitors at the same concentrations as before. Culture
medium was 10ml, log growth phase of bacteria was assessed
by OD600, and the inoculum concentration was 0.1ml. Discs
were impregnated with the antibiotics (all from Sigma-Aldrich)
at the following concentrations: colistin (10µg/ml), rifampicin
(15µg/ml), erythromycin (15µg/ml), kanamycin (1,000µg/ml),
and vancomycin (5µg/ml). The inhibitor discs were placed in the
middle of the agar plates, while the antibiotic discs were placed
equi-distant to the respective inhibitor discs to be tested. The
Kirby-Bauer test was used to assess the zone of inhibition after
24 h. Supplementary Figure 4 shows the agar plates containing
the disks, following completion of the test.
MIC Measurement of Colistin and
Vancomycin in E. coli VCS257 and
S. aureus subsp. aureus Rosenbach
MIC values for colistin and vancomycin were tested for E. coli
and S. aureus, respectively. E. coli and S. aureus suspensions were
prepared in Müller Hinton Broth according to Iqbal et al. (2013).
For E. coli, the concentration of colistin was based on previously
published MIC values for colistin, ranging between 2 and
16µg/ml (Moskowitz et al., 2010; Rojas et al., 2017), and here this
range was further expanded between 0.015µg/ml to 64µg/ml.
MIC values for vancomycin have previously been recorded in the
range of 1.5–2µg/ml (Maclayton et al., 2006; Kshetry et al., 2016;
Goldstein et al., 2018) and in some studies aMIC value of 8µg/ml
and higher has been reported (Alam et al., 2014; Lepe et al., 2014).
Therefore, for S. aureus a MIC confirmation test starting from a
concentration of 8µg/ml was carried out here and thereafter the
MIC was considered accordingly. The doubling dilution method
was used to obtain triplicates of concentrations used for the
antibiotics and a triplicate of control omitting antibiotic was also
prepared. The plates were incubated overnight at 37◦C and the
MIC values of antibiotic treated control wells were compared to
wells where PAD inhibitors were applied in combination with
the antibiotics.
Statistical Analysis
The histograms and graphs were prepared and statistical analysis
was performed using GraphPad Prism version 8 (GraphPad
Software, San Diego, U.S.A.). One-way ANOVA and t-test
analysis were performed, followed by Tukey’s post-hoc analysis.
Significant differences were considered as p ≤ 0.05 and
histograms represent mean of data, with error bars representing
standard error of mean (SEM).
RESULTS
Characterization of Bacterial OMVs/MVs
A poly-dispersed population of OMVs was verified by
nanoparticle tracking (NTA) analysis, with the majority of
vesicles released in the 20–300 nm range for E. coli VCS257,
and similarly in the 37–300 nm range for S. aureus subsp.
aureus Rosenbach (Figures 1A1, 2). This was further
confirmed by transmission electron microscopy, assessing
overall morphology and providing average size estimations
(Figures 1B1, 2). Morphological analysis by TEM revealed
OMVs, including with inner and outer membranes visible, for
E. coli (Figure 1B1) and typical MVs for S. aureus (Figure 1B2).
Western blotting verified the presence of the OMV-specific
marker OmpC (Figure 1C). Changes in OMV size distribution
after PAD-inhibitor treatment in E. coli was reflected in a
change in NTA profile as shown in Figures 1D–G and further
discussed below.
PAD Inhibitors Inhibit OMV Release in the
Gram-Negative Bacterium E. coli VCS257
Effects of the various PAD inhibitors on OMV release in E. coli
are shown in Figure 2. The PAD4-specific inhibitor GSK199
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FIGURE 1 | Characterization of E. coli VCS257 OMVs and S. aureus subsp. aureus Rosenbach MVs using NTA, TEM and Western blotting analysis. (A) NTA curves,
obtained by Nanosight analysis, showing OMVs released from E. coli (A1) and S. aureus (A2) under standard conditions; (B) Negative stain TEM micrographs of E. coli
OMVs (B1) show the presence of a poly-dispersed sample ranging in size from mainly 20 nm to 320 nm (scale bars represent 200 nm), including vesicles showing
(Continued)
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FIGURE 1 | inner and outer membranes for E.coli VCS257 OMVs (B1) and MVs from S. aureus subsp. aureus Rosenbach (B2). (C) OMV-specific marker OmpC
verified by Western blotting. (D–G) NTA profiles of OMVs released from E. coli VCS257 following PAD inhibitor treatment. OMV release profile from E. coli treated for
1 h with PAD inhibitors as follows: (D) Cl-amidine (first generation pan-PAD inhibitor; 50µM); (E) BB-Cl-amidine (second generation pan-PAD inhibitor; 5µM); (F)
AMF30a (PAD2 inhibitor; 5µM); (G) GSK199 (PAD4 inhibitor; 10µM).
showed most potent OMV inhibition with a 66.4% reduction in
OMV release (p= 0.0001), but alsomost significantly affected cell
viability (23.9% reduction, p = 0.0008). BB-Cl-amidine was the
second most potent inhibitor with a 53.8% reduction in OMV
release (p < 0.0001) and a reduction, albeit non-significant (p
= 0.1351), of 19.3% in cell viability, as measured by CFU. Cl-
amidine resulted in a 42.4% inhibition of OMV release (p =
0.0001) and an 18.2% decrease in cell viability (p = 0.0111).
The PAD2-specific inhibitor AMF30a was less effective with a
28.2% reduction in OMV release (p= 0.0116) and caused a 14.7%
reduction in cell viability (p= 0.0283) (Figure 2B). Furthermore,
in addition to reduced total OMV numbers released after PAD
inhibitor treatment, the following changes in OMV profiles were
observed by NTA analysis: Cl-amidine treated E. coli released
OMVs in the size range 20–400 nm, BB-Cl-amidine treated
cells showed OMV release in the 20–500 nm size range, while
AMF30a (PAD2 inhibitor) treatment resulted in an additional
notable peak of OMVs at 501 nm and a second smaller peak
at 701 nm. GSK199 (PAD4 inhibitor) treatment resulted in an
OMV release profile of 20–400 nm, similar to that for Cl-amidine
(Figures 1D–G).
PAD Inhibitors Inhibit Membrane Vesicle
(MV) Release in S. aureus subsp.
aureus Rosenbach
The same range of PAD inhibitors as used with E. coli was used
to examine the effect on membrane vesicle (MV) release from
a Gram-positive bacterium, S. aureus subsp. aureus Rosenbach
(Figure 2C). PAD4-specific inhibitor GSK199 resulted in the
highest inhibition of MV release, with 22.5% reduction (p
= 0.0018), while PAD2 inhibitor AMF30a showed only 3.4%
reduction in OMV release (p = 0.0606). First generation pan-
PAD inhibitor Cl-amidine resulted in a 12.5% inhibition of MV
release (p= 0.0016), and also had the lowest negative impact on S.
aureus cell viability (3.3%, p = 0.0835; Figure 2D), while second
generation pan-PAD inhibitor BB-Cl-amidine showed 7.6% MV
inhibition (p= 0.0061) (Figures 2C,D).
Phylogenetic Reconstruction of E. coli and
S. aureus PAD/AD
Two well supported clades were formed within the Neighbor-
joining phylogeny (Figure 3) based on multiple sequence
alignment of the whole amino acid sequences (using Clustal
Omega), suggesting that E. coli PAD/AD (arginine deiminase
RRM86073.1) is most closely related to human PAD2
(Figure 3A). The E. coli PAD/AD has a shorter, 406 amino
acid (aa) sequence (arginine deiminase EDV68547.1), compared
to human PAD2 (NP031391), PAD3 (AIC56498), and PAD4
(AIC56076), which are 665, 663, and 664 aa, respectively.
Various single, fully conserved residues are found, while some
conservation of similarity between E. coli PAD/AD with human
PAD2 and PAD3 is visible that scores >0.5 in the Gonner PAM
matrix (Supplementary Figure 1). For S. aureus, two well-
supported clades were also formed within the Neighbor-joining
phylogeny (Figure 3B), suggesting that S. aureus PAD/AD
(arginine deiminase BBA25170) is also most closely related to
human PAD2. The S. aureus bacterial PAD/AD has a shorter,
411 aa sequence (BBA25170), similar to that seen for E. coli
PAD/AD, compared to the human PAD2, PAD3, and PAD4
isozymes, which are approximately 664 aa. Various single,
fully conserved residues are found, while some conservation
of similarity between S. aureus PAD/AD to human PAD2 and
PAD3 is visible that scores >0.5 in the Gonner PAM matrix
(Supplementary Figure 2).
Detection of PAD/AD Protein and
Citrullinated/Deiminated Protein Products
in E. coli VCS257
Using Western blotting analysis, E. coli cell and E. coli OMV
protein extracts were assessed for total deiminated proteins, using
the anti-peptidyl-citrulline F95 antibody (MABN328, Merck,
U.K.), as well as for cross-reactivity with human PAD2 (ab50257),
PAD3 (ab169479), and PAD4 (ab96758) antibodies (Figure 4).
For total deiminated proteins (F95), bands in the size range of
15–120 kDa were revealed in both E. coli cells and derived OMVs
(Figure 4A). The presence of a PAD/AD-like protein was verified
in E. coli and derivedOMVs, by the detection of an expected band
at 40–50 kDa, representative of a bacterial PAD/AD (Figure 4B).
Immunoprecipitation of Deiminated
Proteins From E. coli VCS257 and
Derived OMVs
Deiminated proteins from E. coli and derived OMVs were
immunoprecipitated using the Catch and Release R© v2.0
Reversible Immunoprecipitation System (Merck, U.K.)
according to the manufacturer’s instructions and the
anti-peptidyl-citrulline F95 antibody (MABN328, Merck)
(Figures 4C,D and Supplementary Figure 3). As the PAD4
inhibitor GSK199 was here found to be the most effective OMV
inhibitor (Figure 2A), immunoprecipitation using the PAD4
antibody was also carried out on E. coli cell protein extracts, for
identification of putative PAD4 bound proteins (Figure 4 and
Supplementary Figure 3). A range of F95 enriched bands was
seen in both E. coli and OMV samples (Figure 4C). In addition,
the PAD4 enriched eluate showed an F95 positive band in the
expected size range of an E. coli PAD/AD at 45 kDa (Figure 4C,
lane 6, arrow), thus indicating that E. coli PAD/AD itself may also
be deiminated. This band was more prominent when the PAD4
antibody was used for immunoprecipitation from the E. coli
protein lysate, showing a very strong band just below 50 kDa
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FIGURE 2 | Effects of PAD inhibitors on OMV release from E. coli VCS257 and MV release from S. aureus subsp. aureus Rosenbach. (A) All PAD inhibitors showed
significant OMV inhibition in E. coli compared to untreated controls. PAD4 inhibitor GSK199 and second generation pan-PAD inhibitor BB-Cl-amidine were the
strongest inhibitors of OMV release. The PAD2-specific inhibitor AMF30a was less effective. (B) E. coli viability after 24 h PAD inhibitor treatment, represented as CFU.
(C) PAD4 inhibitor GSK199 was the most effective MV inhibitor in S. aureus, reducing MV release by 22.5%. (D) S. aureus viability, represented as CFU, after 24 h
treatment with PAD inhibitors is shown. The experiment was repeated thrice and the data presented are mean ± SEM of the results; exact p-values are indicated.
Concentration of PAD-inhibitors used was as follows: PAD2 inhibitor AMF30a (5µM), PAD4 inhibitor, GSK199 (10µM), pan-PAD inhibitors Cl-amidine (50µM) and
BB-Cl-amidine (5µM).
FIGURE 3 | Neighbor joining tree. The phylogenetic clustering of E. coli (A) and S. aureus (B) PAD/AD, respectively is shown. The evolutionary analysis was inferred
using the Neighbor-Joining method under the conditions of the Poisson distance correction model in MEGA6. Bootstrap values >50 based on 1,000 replicates are
shown as nodal support. Clade 1 contains E. coli (GenBank: EDV68547.1) PAD/AD and Clade 2 contains human PAD2 (GenBank:NP031391), PAD3 (GenBank:
AIC56498) and PAD4 (GenBank: AIC56076).
(Figure 4D, lanes 5–6). When testing the PAD4 bound eluate
with the F95 deimination antibody, several additional positive
bands were detected and may possibly represent deiminated
proteins co-immunoprecipitating with the PAD4 antibody
(Figure 4C; lanes 5 and 6). The F95 eluate from OMVs though
also showed a reaction with the PAD4 antibody (Figure 4D;
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FIGURE 4 | Western blotting of total deiminated proteins and PAD/AD in E. coli VCS257 cells and derived OMVs. (A) E. coli and derived OMVs were analyzed for total
deiminated proteins (F95) as well as for cross-reactivity with human PAD2, PAD3 and PAD4. Bands in the size range of 15–120 kDa were revealed for the
pan-deimination antibody (F95). (B) The human PAD2, 3 and 4 antibodies reacted with a band of 40–50 kDa as expected for a bacterial PAD/AD homolog. Lane 1,
E. coli total protein extract; Lane 2, E. coli OMV protein extract. (C,D) Immunoprecipitated deiminated proteins (F95) and PAD4 bound proteins from E. coli VCS257
and derived OMVs. IP was performed on E. coli total protein and E. coli derived OMVs, using F95 and PAD4 antibodies, respectively. (C) Immunoprecipitated fractions
(F95 enriched and PAD4 bound, respectively) were tested with the pan-deimination F95 antibody. A range of deiminated/citrullinated proteins was observed in E. coli
cells and derived OMVs. Lanes 5 and 6 indicate a deiminated band at 50 kDa corresponding to E. coli PAD/AD (arrow) For lanes 5 and 6 the F95 enriched eluate was
eluted using non-reducing and reducing elution buffer, respectively, and both F95-bound eluates obtained were thereafter run under reducing conditions in the gel. (D)
The same fractions were tested with the PAD4 antibody. Prominent bands around the 50 kDa region (lanes 5–6) correspond to a predicted size of E. coli PAD/AD.
Faint bands of similar sizes are also observed in the OMV F95-enriched samples (lanes 1–2) which may suggest the presence of a PAD/AD which is deiminated in
both E. coli and derived OMVs. The protein standard is indicated in kDa on all blots. For identification of protein hits as assessed by LC-MS/MS for the F95 and PAD4
bound eluates, see Tables 1, 2.
lanes 3 and 4), and therefore may indicate a deiminated PAD/AD
and further deiminated proteins bound to the PAD/AD in E. coli
derived OMVs. Such auto-deimination of the bacterial PAD/AD
will though require further investigation to be fully confirmed.
Liquid Chromatography–Mass
Spectrometry (LC-MS/MS) Analysis of
Deiminated Proteins From E. coli VCS257
and Derived OMVs
Immunoprecipitated proteins (F95 enriched and PAD4 bound)
from E. coli cells and derived OMVs were analyzed by LC-
MS/MS (Figures 5, 6 and Tables 1, 2). Nine deiminated proteins
were identified in the F95 enriched E. coli OMV protein sample
(Figures 5, 6A). The 30s ribosomal protein S15 was unique to
OMVs. As threonine-tRNA ligase (thrS), has not been reported
in E. coli OMVs before, STRING (Search Tool for the Retrieval
of Interacting Genes/Proteins) analysis (https://string-db.org/)
was carried out to assess if thrS is interconnected with the
other proteins in the OMV associated proteins (Figure 6B). This
showed five of the nine proteins to be associated with each
other, at least through text mining. Furthermore, the E. coli
OMV-associated thrS is co-expressed with 30s ribosomal protein
S15 (rpsO), 30s ribosomal protein S4 (rpsD) and 50S ribosomal
protein L22 (rplY), as well as being experimentally determined to
interact with rplY (Figure 6B).
Table 1 lists proteins identified in E. coli cell samples that
were unique in F95 enriched eluates. Table 2A lists proteins
that were identified in the PAD4 enriched eluates from E. coli
cells, indicative of PAD4 bound proteins. Table 2B summarizes
common proteins identified in all three eluates (F95 enriched
eluate from E. coli cells, F95 enriched eluate from OMVs, PAD4
enriched eluate from E. coli cells); proteins are shown that had
two or more peptides identified and a protein score of >50.
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FIGURE 5 | Deiminated proteins and PAD4 bound proteins identified in E. coli VCS257 cells and derived OMVs. The Venn diagram shows F95 enriched proteins
identified from E. coli cells and E. coli OMVs, as well as PAD4 bound proteins identified from E. coli cells. Four proteins were common to all three eluates (for further
details on protein identification see Tables 1, 2).
PAD Inhibitor Treatment Enhances
Antibiotic Sensitivity of E. coli VCS257
Kanamycin was the most effective antibiotic against E. coli in
the absence of PAD inhibitors (Figure 7A). In the presence of
PAD inhibitors, GSK199 most significantly enhanced the effects
of erythromycin, measured as a percentage increase in the zone
of inhibition on the lawn of E. coli, by 88.9% (p = 0.0025);
that of rifampicin by 56.7% (p = 0.0561) and that of colistin
by 14.6% (p = 0.2495). BB-Cl-amidine was most effective when
used in combination with rifampicin, increasing the zone of
inhibition by 106.45% (p = 0.0025) and that of kanamycin
by 65.6% (p = 0.0186). Cl-amidine caused enhancement of
antibiotic sensitivity in combination with rifampicin (43.8%; p
= 0.045), erythromycin (35.6%; p = 0.0572), and kanamycin
(38.8%; p = 0.0390), compared to antibiotic alone (Figure 8).
AMF30a was not effective in sensitizing E. coli to any of the
antibiotics tested (see Supplementary Figure 4A, showing the
agar plates). Importantly, there were no zones of inhibition seen
in the agar plates which were only treated with the inhibitor discs,
thus ruling out any inhibition on bacterial growth in the absence
of antibiotics (Supplementary Figure 4B).
PAD Inhibitors Enhance Antibiotic
Sensitivity of S. aureus subsp. aureus
Rosenbach
PAD inhibitors significantly enhanced antibiotic effectivity
against S. aureus (Figure 7B). For erythromycin, BB-Cl-amidine
significantly enhanced antibacterial effects, by 18.2% (p =
0.0234). For vancomycin, GSK199 was most effective, with a
69.3% increase in antibiotic effectivity (p = 0.0250), while Cl-
amidine was also significant (42.7%, p = 0.0354). (Figure 7B).
For rifampicin, GSK199 and Cl-amidine significantly increased
the zone of inhibition (10.1%; p = 0.0202) and 6.4%; p =
0.0239, respectively). The antibacterial effects of kanamycin
were also significantly increased by both Cl-amidine and BB-
Cl-amidine by 20.8% (p = 0.0055) and 28.9%; (p = 0.0101),
respectively. For colistin, Cl-amidine increased the zone of
inhibition by 21.5% (p = 0.0444). There were no zones
of inhibition seen in the agar plates treated with the PAD
inhibitor discs alone, indicating no effect on bacterial growth
(Supplementary Figures 4C,D).
PAD Inhibitors Decrease MIC Value of
Colistin Against E. coli VCS257
As the minimum inhibitory concentration (MIC) value of
colistin against Gram-negative bacteria has been inconsistently
reported in the literature it was further investigated here
(Figure 8A). BB-Cl-amidine and Cl-amidine resulted in
91.6% (p = 0.0001) and 87.4% (p = 0.0002) reduction
in MIC, respectively, while GSK199 lowered the MIC by
76% (p = 0.0004) (Figure 8A). There were no zones of
inhibition seen in the plates which were only treated with
the inhibitor discs, indicating no bactericidal effect due to
inhibitors alone.
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FIGURE 6 | Deiminated proteins in E. coli VCS257 OMVs. Deiminated proteins were isolated by immunoprecipitation using the F95 antibody and analyzed by
LC-MS/MS. (A). All deiminated proteins identified in the OMV sample, with a score >50 are listed. Ions score is −10*Log (P), where P is the probability that the
observed match is a random event. Individual ions scores >16 indicated identity or extensive homology (p<0.05). Protein scores were derived from ions scores as a
non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score 20. Values with 2 or more peptides per protein and a score of >50 were considered.
(B). String analysis of the deiminated proteins identified in E. coli OMVs. Out of 9 proteins, 5 were associated with each other, at least through text mining.
PAD Inhibitors Decrease MIC Value of
Vancomycin Against S. aureus subsp.
aureus Rosenbach
The MIC value of vancomycin against S. aureus has been
inconsistently reported in the literature and was thus investigated
further. Figure 8B shows the effect of the most effective MV-
inhibiting PAD inhibitors on the MIC of vancomycin; Cl-
amidine showed a 62.5% reduction (p = 0.0022) while GSK199
lowered MIC by 25% (p = 0.0161) (Figure 8B). There was no
effect on MIC of colistin in the presence of inhibitors alone.
DISCUSSION
For analysis of bacterial OMV/MVs in this study, isolation
and quantification approaches using ultracentrifugation and
NTA analysis were used, similar as performed by other groups
(McCaig et al., 2013; Klimentova and Stulik, 2015; Roier et al.,
2016). OMVs have previously been reported to fall mainly in
the size range 10–300 nm (Kulkarni et al., 2015; Huang et al.,
2016), and similar profiles were observed here. OMVs were
also further characterized morphologically using TEM, and by
Western blotting analysis using the outer membrane specific
marker, OmpC (Figure 1). Furthermore, some change in OMV
profile was observed in response to PAD inhibitor treatment,
and this varied between inhibitors used, showing a change in
shift of vesicle size populations after treatment with the different
PAD inhibitors.
Here, an E. coliVCS257 citrullinomewas identified for the first
time, using F95 enrichment and LC-MS/MS analysis, confirming
the presence of deiminated/citrullinated proteins in E. coli cells
and E. coli derived OMVs. In bacteria, studies on PAD/AD
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TABLE 1 | Deiminated proteins identified by F95 enrichment in E. coli
VCS257cells.
UniProt ID Protein name Abbreviation MS2 Intensity Score (p < 0.05)a
B7MQF2 Trigger factor tig 81193 192.72
B7NKH1 UPF0227 protein
YcfP
ycfP 11941 166.86
B7MSJ0 RNA-binding
protein Hfq
hfq 256917 132.47
Q1R638 50S ribosomal
protein L17
rplQ 126430 128.85
Q1R602 50S ribosomal
protein L3
rplC 69461 254.77
Q1R619 50S ribosomal
protein L24
rplX 6484.4 75.48
B7N255 Protein-export
protein SecB
secB 136512 77.044
P14407 Fumarate
hydratase class
I, anaerobic
fumB 15233 78.27
P0A9S6 Glycerol
dehydrogenase
gldA 220449 441.19
P69799 PTS system
mannose-
specific EIIAB
component
manX 94232 56.71
B7MRV6 Serine-tRNA
ligase
serS 16845 55.11
a Ions score is−10*Log(P), where P is the probability that the observed match is a random
event. Individual ions scores >16 indicated identity or extensive homology (p < 0.05).
Protein scores were derived from ions scores as a non-probabilistic basis for ranking
protein hits. Cut-off was set at Ions score 20. Values with 2 or more peptides per protein
and a score of >50 were considered.
Deiminated proteins were isolated by immunoprecipitation using the pan-deimination F95
antibody and analyzed by LC-MS/MS. Peak files were submitted to Mascot.
homologs have been limited and hitherto mainly reported in
P. gingivalis (Mangat et al., 2010; Bielecka et al., 2014); a
Gingivalis citrullinome has also been described (Stobernack et al.,
2016). An E. coli PAD/AD-like protein was detected here at
approximatly 40–50 kDa, similar to that found in P. gingivalis
(Bielecka et al., 2014; Gabarrini et al., 2018), while in comparison
human PADs are 72–75 kDa (Vossenaar et al., 2003; Kosgodage
et al., 2018). Multiple sequence analysis of E. coli and S. aureus
suggested that PAD/AD of E. coli and S. aureus are most closely
related to human PAD2.
Interestingly, for inhibiting OMV/MV release from Gram-
negative and Gram-positive bacteria the PAD4-specific inhibitor
GSK199 was most effective while the PAD2-specific inhibitor
AMF30a was least effective. Therefore, it may be postulated that
the tertiary conformation of both E. coli and S. aureus PAD/ADs
may be more similar to human PAD4, although the amino acid
sequence alignment analysis indicates more similarity to PAD2,
and this will require further investigation. In P. gingivalis, also a
Gram-negative bacterium, PAD is believed to be evolutionarily
only remotely related to human PAD2 despite the fact that both
catalyze the same chemical reaction (Rodríguez et al., 2009;
Bereta et al., 2019) and furthermore, point-mutation variants
with differing deimination activity have also been reported in
Gingivalis (Gabarrini et al., 2018; Bereta et al., 2019).
Here, F95 enrichment analysis revealed a range of deiminated
proteins, both in E. coli cells and their derived OMVs,
indicating lateral transfer of deiminated proteins via OMVs.
Besides roles in bacterial communication, this may possibly
also affect host-pathogen interactions, including immune
evasion via modification of the host’s proteins. For example,
citrullination/deimination of complement component C5a,
upon treatment with P. gingivalis OMVs, as opposed to in vitro
treatment of C5a with PAD, has been shown to contribute to
bacterial immune evasion by decreasing the chemotactic ability
of neutrophils (Bielecka et al., 2014).
The citrullinome of E. coli VCS257 observed here, revealed
indeed a range of metabolic, stress-response related and
membrane proteins, therefore indicating diverse roles for protein
deimination in bacterial cell function. Deiminated proteins
identified in E. coli derived OMVs included threonine-tRNA
ligase, which has not been described as being deiminated in
bacterial OMVs before, but has been shown to be in OMVs
from Streptococcus suis (Haas and Grenier, 2015), albeit not
in deiminated form. Threonine-tRNA ligase, also known as
threonine-tRNA synthetase, belongs to the family of aminoacyl-
tRNA synthetases, which are involved in RNA splicing and
transcriptional and translational regulation. They link amino
acids to their cognate transfer RNAs (tRNA) in aminoacylation
reactions, that establish the connection between a specific amino
acid and a nucleotide triplet anticodon embedded in the tRNA
(Schimmel, 2008). Also, 30S ribosomal protein was identified
as being deiminated in OMVs. It is one of the primary rRNA
binding proteins that bind directly to 16S rRNA, where it
helps nucleate assembly of the platform of the 30S subunit by
binding and bridging several RNA helices of the 16S rRNA
(Smith et al., 2018). In addition, 30S ribosomal protein S4
(rpsD) and S15 (rpsO) were identified as deiminated both in
the E. coli cells as well as their derived OMVs. Previously,
40S ribosomal protein has been reported as a substrate of
PAD4 mediated deimination/citrullination in HEK 293Tcells
(Guo et al., 2011).
Furthermore, evidence of a PAD/AD-like protein exported in
E. coli VCS257 derived OMVs was found. When probing the
PAD4 enriched eluate with the F95 antibody, a faint positive
band in the expected range for a putative bacterial PAD/AD,
in the region of 50 kDa region was observed, indicating that
possibly the E. coli PAD/AD may be deiminated itself, although
the LCMS-MS analysis did not reveal a PAD/AD-like protein hit.
Such a possibility of PAD/AD auto-deimination would though
align with previous studies on auto-deimination of mammalian
PAD4 (Slack et al., 2011) but will require further in-depth
investigation. In a recent study on OMVs derived from P.
gingivalis, it was found that Gingivalis PAD was abundant in
OMVs, although no assessment was made of a deiminated
PAD form or of deiminated proteins exported in OMVs
(Gabarrini et al., 2018).
The effect of PAD inhibitors on OMV/MV release, as
previously established for EV release in eukaryotic cells (Kholia
et al., 2015; Kosgodage et al., 2017, 2018; Gavinho et al., 2019),
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TABLE 2A | PAD4 bound proteins identified in E. coli VCS257 cells.
UniProt ID Protein name Abbreviation MS2 Intensity Scorea (p<0.05)
P0A895 Lysine-tRNA ligase, heat inducible lysU 321997 300.12
Q8X9L0 ATP-dependent zinc metalloprotease FtsH ftsH 1E+06 151.09
B7MRC1 Regulator of sigma D rsd 23402 247.53
P0ABC5 Modulator of FtsH protease HflC hflC 66850 189.23
Q1R5V0 50S ribosomal protein L10 rplJ 478659 218.99
Q8X4S5 Arabinose 5-phosphate isomerase GutQ gutQ 486219 120.37
Q1R6A9 50S ribosomal protein L13 rplM 99365 135.62
P0AA45 Ribosomal small subunit pseudouridine synthase A rsuA 50727 162.27
A7ZML6 Succinylornithine transaminase astC 232079 73.58
B7MPT2 Curved DNA binding protein cbpA 6123.2 90.68
P69911 Glutamate decarboxylase beta gadB 387378 72.46
A7ZY39 Cyclic pyranopterin monophosphate synthase accessory
protein
moaC 17232 67.03
Q1R613 50S ribosomal protein L16 rplP 475140 95.53
Q1R358 30S ribosomal protein S18 rpsR 312269 103.87
P07014 Succinate dehydrogenase iron-sulfur subunit sdhB 48651 157.85
P42632 PFL-like enzyme TdcE tdcE 29499 66.01
P0AGL3 Putative reactive intermediate deaminase TdcF tdcF 161746 80.57
Q8X7I0 UPF0339 protein YegP yegP 6121.7 87.63
Q0TFD0 Acetyl-coenzyme A carboxylase carboxyl transferase
subunit-β
accD 156916 99.12
P0A6A5 Acetate kinase ackA 79146 70.42
P0A9Q3 Aerobic respiration control protein ArcA arcA 19035 60.23
A8A0U0 Succinylornithine transaminase astC 28022 73.51
P0A9H4 Inducible lysine decarboxylase cadA 716567 78.26
Q8FJM0 DNA protection during starvation protein dps 51562 65.43
B7N1L1 Glycine-tRNA ligase beta subunit glyS 23006 87.76
B7N2S2 ATP-dependent protease ATPase subunit HslU HslU 398703 52.01
B7N2Q7 ATP-dependent 6-phosphofructokinase isozyme 1 pfkA 57552 62.75
B7UJ59 Polyribonucleotide nucleotidyltransferase Pnp 5914.7 70.94
B7MZ76 CTP synthase pyrG 17163 59.39
B6I184 50S ribosomal protein L25 rplY 56618 57.85
Q0TA78 DNA-directed RNA polymerase subunit beta rpoB 102175 72.91
B6HZE3 30S ribosomal protein S2 rpsB 226035 68.17
B7NGD4 30S ribosomal protein S6 rpsF 151007 61.19
C4ZUJ7 30S ribosomal protein S12 rpsL 396281 110.55
Q8XBT3 Universal stress protein G uspG 36115 159.67
P0AF94 2-iminobutanoate/2-iminopropanoate deaminase yjgF 22468 105.18
a Ions score is −10*Log (P), where P is the probability that the observed match is a random event. Individual ions scores > 16 indicated identity or extensive homology (p < 0.05).
Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score 20. Values with 2 or more peptides per protein and a
score of >50 were considered.
Proteins were isolated by immunoprecipitation using the PAD4 antibody (ab96758) and analyzed by LC-MS/MS. Peak files were submitted to Mascot.
TABLE 2B | Proteins identified both in F95 and PAD4 enriched samples of E. coli VCS257 cells and derived OMVs.
MS2 intensity
UniProt ID Protein name Abbreviation E. coli F95 E. coli PAD4 OMV F95 Scorea (p<0.05)
Q1R6H3 30S ribosomal protein S15 rpsO 128707 61762 67181 585.62
P04949 Flagellin fliC 704599 1E+06 9488.7 653.24
P0A906 Outer membrane lipoprotein SlyB slyB 289574 555800 10565 632.79
Q1R636 30S ribosomal protein S4 rpsD 22719 44378 3554.4 289.35
a Ions score is −10*Log (P), where P is the probability that the observed match is a random event. Individual ions scores > 16 indicated identity or extensive homology (p < 0.05).
Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score 20. Values with 2 or more peptides per protein and a
score of >50 were considered.
Proteins commonly identified by LC-MS/MS in both F95 and PAD4 enriched protein eluates are listed.
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reveals a phylogenetically conserved pathway from bacteria to
mammals. This is also in line with findings that many commonly
expressed proteins including chaperone proteins, ribonuclease,
outer membrane lipoprotein, 50S ribosomal protein L22 and
flagellin are believed to be targets of protein deimination (Huang
et al., 2016; Claushuis et al., 2018). Importantly, the present
study shows that PAD inhibitors can be used to enhance
antibiotic sensitivity of selected antibiotics. PAD4 inhibitor
GSK199, alongside the pan-PAD inhibitors were effective for
OMV/MV inhibition and sensitization to antibiotic treatment.
Differences in mechanisms of action for the selected PAD
inhibitors used in this study may need to be considered, both
with regards to inhibiting vesicle release and the synergism
observed with each antibiotic. Interestingly, while PAD4-
inhibitor GSK199 was overall the strongest OMV/MV inhibitor,
albeit the pan-PAD inhibitors showed a similar trend, in
some cases the pan-PAD inhibitors (Cl-am and BB-Cl-am)
were more effective in sensitization to antibiotic treatment.
It must also be taken into consideration that BB-Cl-amidine
and Cl-amidine are hydrophilic, while AMF30a and GSK199
are hydrophobic compounds. Furthermore, GSK199 is highly
lipophilic which may facilitate its uptake in the cell. The
difference in hydrophobicity of the PAD inhibitors could have
played a role in cell penetration, in addition to differing in
specificity for inhibition of the bacterial PAD/AD, and this
may therefore also have affected OMV/MV release. A recent
review has demonstrated the presence of different types of
vesicles released from both Gram-negative and Gram-positive
bacteria, indicating also that the composition of the cell
membrane plays a role in vesiculation (Toyofuku et al., 2019).
The presence of a thickened peptidoglycan cell wall in Gram-
positive bacteria restricts the penetration of most drugs into
the cells, which suggests the need of an alternative receptor-
mediated transport system (Liu et al., 2018). However, the
high lipid content of the Gram-negative cell membrane with
a thin layer of peptidoglycan increases membrane fluidity thus
facilitating OMV release (Roier et al., 2016). This may also
facilitate the bacterial cell wall penetration of lipid soluble drugs
and elicit a more effective response, as indeed observed here
for GSK199.
While PAD4-mediated neutrophil extracellular trap (NET)
formation is a well-known bactericidal and anti-pathogenic
mechanism of the immune system (Li et al., 2010; Claushuis
et al., 2018; Magnadóttir et al., 2018), we have now revealed
here another antibacterial mechanism, namely via PAD/AD-
mediated inhibition of bacterial OMV/MV release. Bacteria may
indeed utilize their PAD/AD in several ways for modulation
of the host immune system and immune invasion, including
via the generation of neo-epitopes, modification of host’s
immune proteins, such as C5a, and also through the release
of OMV/MVs. While many studies on OMVs have been
based on Gram-negative bacterial species (Pérez-Cruz
et al., 2013; Bonnington and Kuehn, 2016; Roier et al.,
2016), MV release from S. aureus has also been shown
by different groups (Lee et al., 2009; Gurung et al., 2011).
Interestingly, MV secretion and improper vancomycin
treatment have been correlated with biofilm formation
by methicillin-resistant Staphylococcus aureus (MRSA)
(He et al., 2017).
When assessing the effectivity of PAD inhibition to enhance
susceptibility of Gram-positive and Gram-negative bacterial
species to antibiotic treatment, E. coli VCS257 were rendered
more sensitive to erythromycin, rifampicin, kanamycin and
colistin, while S. aureus subsp. aureus Rosenbach became more
sensitive to all five antibiotics tested. This increased sensitivity
in both bacterial species varied though somewhat, depending
on the PAD-specific inhibitors used. It must also be noted
that while the zone of inhibition was statistically significant in
S. aureus, the proportional differences observed in antibiotic
sensitization were not as high as those observed in some cases
for E. coli and therefore it will require further investigation
how physiologically significant such lower, albeit statistically
significant, effects are. It can also be postulated that bacteria
may use PAD/AD mediated deimination as a mode of a hitherto
non-described microbial strategy to evade antibiotic action,
and this might also explain some differences observed with
the different PAD inhibitors and will require further in-depth
investigation. There was no antibacterial effect of vancomycin
on E. coli VCS257, confirming its limited effectiveness on
Gram-negative species and the previously established resistance
of E. coli to vancomycin, due to its inability to significantly
penetrate the outer membrane (Zhou et al., 2015). Here,
colistin and vancomycin effectivity was found to be enhanced
in the presence of PAD inhibitors in E. coli and S. aureus
respectively, decreasing MIC value at varying degrees. This
indicates that lower concentrations of the antibiotic may be
used to treat infections with minimal damage to healthy cells.
It has previously been shown that the presence of calcium
decreases the bactericidal effect of colistin on Paenibacillus
polymyxa, which suggests that Ca2+ modulates a protective
barrier against colistin (Yu et al., 2015). As the PADs are
calcium-activated enzymes, it can be postulated that downstream
PAD/AD activation and resulting OMV/MV release via a
PAD/AD pathway may be a measure of bacterial defense against
colistin treatment.
Our current study is the first to describe effects of PAD
inhibitors on OMV/MV release in both a Gram-positive
and Gram-negative bacterial species. PAD/AD inhibition
approaches in bacteria have previously been discussed in
relation to oral Gingivalis and the association to initiation of
autoimmunity via the generation of neo-epitopes (Mangat
et al., 2010; Montgomery et al., 2016). Pharmacological
inhibition of PADs, using Cl-amidine or a PAD2/PAD4
inhibitor has also been shown to improve survival in several
murine models of sepsis and LPS-induced endotoxemia
(Zhao et al., 2016; Biron et al., 2017; Liang et al., 2018).
Here we have shown that PAD inhibition had a significant
effect on antibiotic sensitization in both species, albeit to a
lower extent in S. aureus. Therefore, further identification
and assessment of candidate OMV/MV inhibitors may
allow for tailored application according to bacteria type
and specific antibiotics.
Previous studies have discussed the use of OMVs for
example as drug delivery vehicles (Ellis and Kuehn, 2010;
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FIGURE 7 | PAD inhibitors increase antibiotic sensitivity of E. coli VCS257 and S. aureus subsp. aureus Rosenbach. (A) In E. coli, all antibiotics (Ab), except for
vancomycin, had significantly increased zones of inhibition in the presence of PAD inhibitors. BB-Cl-amidine, Cl-amidine and GSK199 were effective, increasing
antibiotic sensitivity of E. coli to erythromycin, rifampicin, kanamycin and colistin. Vancomycin was not effective against Gram-negative bacterial colonies and did not
result in a zone of inhibition in the presence of any of the PAD inhibitors. (B) In S. aureus, vancomycin, rifampicin, kanamycin and colistin significantly increased their
zones of inhibition in the presence of PAD inhibitors. BB-Cl-amidine enhanced bactericidal effects of erythromycin, while vancomycin was enhanced by GSK199 and
Cl-amidine. Anti-bacterial effects of rifampicin were enhanced by GSK199 and Cl-amidine. Kanamycin’s zone of inhibition was increased by Cl-amidine and
BB-Cl-amidine. For colistin, the zone of inhibition was increased by Cl-amidine. Concentration of PAD-inhibitors used was as follows: PAD2 inhibitor AMF30a (5µM),
PAD4 inhibitor, GSK199 (10µM), pan-PAD inhibitors Cl-amidine (50µM) and BB-Cl-amidine (5µM). The experiments were carried out three times and the data
presented are mean ± SEM of the results (*p ≤ 0.05; **p ≤ 0.01).
Gujrati et al., 2014; Gerritzen et al., 2017; Jain and Pillai,
2017; Jan, 2017; Wang et al., 2018). OMVs have also been
tested as delivery vehicles for targeted gene silencing using
siRNA-packaged OMVs (Alves et al., 2016), although the
exact mechanism for packaging proteins and other reagents
in OMVs still remains to be fully understood. There is
also an increasing interest in identification of OMV sub-
populations (Pérez-Cruz et al., 2016; Bonnington and Kuehn,
2017; Turner et al., 2018; Cooke et al., 2019; Toyofuku
et al., 2019; Zavan et al., 2019), as well as in assessing the
importance of OMV size for cellular uptake and entry
(Turner et al., 2018). Therefore, changes observed here in
the NTA spectra of OMVs in response to PAD inhibitor
treatment (Figures 1D–G) may be of some interest in
addition to the observed reduction in total amounts of
OMV/MVs released.
For the first time, the potential of using PAD inhibitors
to enhance antibiotic sensitivity has been assessed, in both a
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FIGURE 8 | PAD inhibitors reduce the MIC value of colistin for E. coli VCS257 and MIC value of vancomycin for S. aureus subsp. aureus Rosenbach. (A) In E. coli,
BB-Cl-amidine was most effective at lowering the MIC value of colistin, reducing MIC by 91.6%. Cl-amidine decreased MIC by 87.4%, being the second most
effective OMV-inhibitor lowering the MIC value of colistin. GSK199 lowered MIC by 76%. The experiment was repeated thrice and the data presented are mean ±
SEM of the results; exact p-values are indicated. (B) In S. aureus, Cl-amidine increased the effectiveness of vancomycin by at least 62.5%, while GSK199 resulted in a
25% decrease in MIC. The experiments were repeated thrice and the data presented are mean ± SEM of the results; exact p-values are shown.
Gram-positive and Gram-negative bacterial species, revealing
a phylogenetically conserved PAD/AD pathway of membrane
vesicle release. This may open avenues for tailored OMV/MV
inhibition in combination with selected antibiotics, according
to bacterial type, to regulate biofilm formation and tackle
antibiotic resistance.
CONCLUSION
This study reveals a phylogenetically conserved PAD/AD
pathway of OMV/MV release in bacteria that can be
pharmacologically modulated to sensitize bacteria to
antibiotic treatment. For the first time, a citrullinome
of E. coli VCS257 and associated OMVs is described,
indicating lateral transfer of deiminated proteins via
OMVs. Our findings highlight new applications for
PAD inhibitors to regulate OMV/MV release and to
enhance antibiotic sensitivity in both Gram-positive and
Gram-negative bacteria.
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Supplementary Figure 1 | Multiple sequence alignment of E. coli AD and
human PADs. The evolutionary relationship between E. coli AD and human
PAD2, 3 and 4 is shown; (∗) indicates positions which have a single, fully
conserved residue; (:) indicates conservation between groups of strongly similar
properties - scoring >0.5 in the Gonnet PAM 250 matrix; (.) indicates
conservation between groups of weakly similar properties, scoring <0.5 in the
Gonnet PAM 250 matrix.
Supplementary Figure 2 | Multiple sequence alignment of S. aureus AD and
human PADs. The evolutionary relationship between S. aureus AD and human
PAD2, 3 and 4 is shown; (∗) indicates positions which have a single, fully
conserved residue; (:) indicates conservation between groups of strongly similar
properties—scoring >0.5 in the Gonnet PAM 250 matrix; (.) indicates conservation
between groups of weakly similar properties, - scoring <0.5 in the Gonnet PAM
250 matrix.
Supplementary Figure 3 | Western blotting of immunoprecipitated deiminated
proteins (F95) and PAD4 bound proteins from E. coli VCS257 and derived OMVs.
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(A) Same figure as 4C, but also showing unbound fractions (flow-through) from
OMVs and E. coli after IP, using the F95 antibody. (B) Same figure as 4D, but also
showing unbound fractions (flow-through) from OMVs and E. coli after IP, using
the PAD4 antibody.
Supplementary Figure 4 | Agar plates showing the Kirby-Bauer disk diffusion
test for E. coli VCS257 and S. aureus subsp. aureus Rosenbach. (A) Disk
diffusion test for E. coli VCS257. (B) Effects of PAD inhibitor disks alone on E. coli
are shown. (C) Disk diffusion test for S. aureus subsp. aureus Rosenbach. (D)
Effects of PAD inhibitors alone on S. aureus are shown. Disks containing the
following antibiotics are indicated: erythromycin (E), vancomycin (V), Rifampicin
(R), kanamycin (K), colistin (C). PAD inhibitors used were GSK199 (10µM; PAD4
inhibitor), Cl-amidine (50µM; pan-PAD inhibitor), BB-Cl-amidine (5µM; pan-PAD
inhibitor), AMF30a (5µM; PAD2 inhibitor).
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